The loss of Emergent BioSolutions under GAAP for the 3 months of 2022 was $3.7 million, compared to a profit of $69.7 million in the previous year. Revenue decreased 10.3% to $307.5 million from $343 million a year earlier.
The loss of Emergent BioSolutions under GAAP for the 3 months of 2022 was $3.7 million, compared to a profit of $69.7 million in the previous year. Revenue decreased 10.3% to $307.5 million from $343 million a year earlier. 
sec.gov
English (US) 